Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q1 2020 · 10-Q
Revenue$25.35M$25.35M−55.5% vs Q1 2019 Net Income-$6.10M-$6.10MN/M vs Q1 2019 EPS Diluted-$0.04-$0.04N/M vs Q1 2019 Gross Profit$2,360,000−36.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flow-$4,844,000N/M Free Cash Flowderived-$4,958,000N/M Margins · derivedGross margin9.3%+2.7 pt vs Q1 2019
Operating margin-12.7%−17.9 pt vs Q1 2019
Net margin-24.1%−27.2 pt vs Q1 2019
ended Mar 31, 2020 · filed May 11, 2020 · 41 d after period end